发布求助
文献互助 智能选刊 最新文献

Journal of the American Academy of Dermatology最新文献

筛选
英文 中文
Nail disorders in pediatric patients: Part 2. Clinical overview, diagnosis and management of inflammatory, pigmentary, and neoplastic etiologies. 儿科患者指甲疾病：第2部分。临床概述，诊断和管理炎症，色素，和肿瘤病因。
IF 12.3 1区 医学
Journal of the American Academy of Dermatology Pub Date : 2026-10-19 DOI: 10.1016/j.jaad.2026.10.032
Jose W Ricardo, Jane S Bellet, Bianca Maria Piraccini, Bertrand Richert, Adam I Rubin, Antonella Tosti, Shari R Lipner
{"title":"Nail disorders in pediatric patients: Part 2. Clinical overview, diagnosis and management of inflammatory, pigmentary, and neoplastic etiologies.","authors":"Jose W Ricardo, Jane S Bellet, Bianca Maria Piraccini, Bertrand Richert, Adam I Rubin, Antonella Tosti, Shari R Lipner","doi":"10.1016/j.jaad.2026.10.032","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.10.032","url":null,"abstract":"<p><p>Nail disorders represent a relatively uncommon but diverse group of conditions seen in pediatric patients. Management varies largely by etiology. Some inflammatory nail disorders in children are self-limited, whereas others may lead to permanent nail loss if not recognized and treated early. In addition, certain nail disorders may present differently in children than adults and may suggest increased systemic disease burden. In Part 2 of this two-part continuing medical education series, we review inflammatory, pigmentary, and neoplastic nail disorders in children and propose clinical approach algorithms for pediatric nail psoriasis and longitudinal melanonychia.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nail disorders in pediatric patients: Part 1. Clinical overview, diagnosis and management of physiological variants, and congenital, hereditary, and infectious etiologies. 儿科患者的指甲疾病：第1部分。临床概述，诊断和管理生理变异，和先天性，遗传性和感染性病因。
IF 12.3 1区 医学
Journal of the American Academy of Dermatology Pub Date : 2026-10-19 DOI: 10.1016/j.jaad.2026.10.031
Jose W Ricardo, Jane S Bellet, Bianca Maria Piraccini, Bertrand Richert, Adam I Rubin, Antonella Tosti, Shari R Lipner
{"title":"Nail disorders in pediatric patients: Part 1. Clinical overview, diagnosis and management of physiological variants, and congenital, hereditary, and infectious etiologies.","authors":"Jose W Ricardo, Jane S Bellet, Bianca Maria Piraccini, Bertrand Richert, Adam I Rubin, Antonella Tosti, Shari R Lipner","doi":"10.1016/j.jaad.2026.10.031","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.10.031","url":null,"abstract":"<p><p>Nail disorders in children are relatively common and anxiety-provoking for families, yet frequently underrecognized in clinical practice. Many nail disorders in children require no treatment or are readably treatable; however, unfamiliarity may lead to unnecessary, inappropriate, or delayed treatment. In this part 1 of a 2-part continuing medical education series we review physiological variants and congenital, hereditary, and infectious nail disorders, and provide diagnostic and management tips for dermatologists managing these conditions.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stimulants May Be a Culprit in Patients with both Erythromelalgia and Raynaud's phenomenon: A Retrospective Cohort Study. 兴奋剂可能是红斑性肢痛和雷诺现象患者的罪魁祸首：一项回顾性队列研究。
IF 12.3 1区 医学
Journal of the American Academy of Dermatology Pub Date : 2026-10-19 DOI: 10.1016/j.jaad.2026.10.045
Rachel L Ziebart, Ana I Casanegra, Mark D Davis, Julio C Sartori-Valinotti
{"title":"Stimulants May Be a Culprit in Patients with both Erythromelalgia and Raynaud's phenomenon: A Retrospective Cohort Study.","authors":"Rachel L Ziebart, Ana I Casanegra, Mark D Davis, Julio C Sartori-Valinotti","doi":"10.1016/j.jaad.2026.10.045","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.10.045","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative Complications Following Malignant Skin Excision in Patients Using Glucagon-Like Peptide-1 Receptor Agonists: A 5-Year Retrospective Cohort Analysis Using TriNetX. 恶性皮肤切除术后使用胰高血糖素样肽-1受体激动剂的患者的术后并发症：使用TriNetX的5年回顾性队列分析
IF 12.3 1区 医学
Journal of the American Academy of Dermatology Pub Date : 2026-10-19 DOI: 10.1016/j.jaad.2026.10.046
Maximillion W Hayama, Vanessa Lazaro-Camp, Joey Liang, Justin Zhang, Cynthia L Green, Michelle Pavlis
{"title":"Postoperative Complications Following Malignant Skin Excision in Patients Using Glucagon-Like Peptide-1 Receptor Agonists: A 5-Year Retrospective Cohort Analysis Using TriNetX.","authors":"Maximillion W Hayama, Vanessa Lazaro-Camp, Joey Liang, Justin Zhang, Cynthia L Green, Michelle Pavlis","doi":"10.1016/j.jaad.2026.10.046","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.10.046","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psoriasis: Which therapy for which patient, updated, part I. Focus on Psoriasis Comorbidities and Preferred Systemic Agents. 银屑病：哪一种治疗适合哪一名患者，更新，第一部分：关注银屑病合并症和首选全身药物。
IF 12.3 1区 医学
Journal of the American Academy of Dermatology Pub Date : 2026-10-19 DOI: 10.1016/j.jaad.2026.09.132
Anusha Pasumarthi, Kateryna Karpoff, Mark Lebwohl
{"title":"Psoriasis: Which therapy for which patient, updated, part I. Focus on Psoriasis Comorbidities and Preferred Systemic Agents.","authors":"Anusha Pasumarthi, Kateryna Karpoff, Mark Lebwohl","doi":"10.1016/j.jaad.2026.09.132","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.09.132","url":null,"abstract":"<p><p>Patients with psoriasis (PsO) may have various comorbidities, that are either related to or unrelated to the disease itself. Selection of the appropriate treatment modality has evolved substantially with the rapid expansion of available options that can be individualized based on patients' comorbidity profiles, extent of disease, prior therapeutic response, and treatment preferences. This first article of a two-part series focuses on selecting systemic therapy for PsO patients with specific inflammatory comorbidities or a history of malignancy.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Who May See the Image? Patient Privacy After Clinical Photography. 谁可以看到图像？临床摄影后的患者隐私。
IF 12.3 1区 医学
Journal of the American Academy of Dermatology Pub Date : 2026-10-19 DOI: 10.1016/j.jaad.2026.10.038
Ikenna Nebo, Rachel Ma, Ananya Eeraveni, Tamia L Ward, Jane M Grant-Kels
{"title":"Who May See the Image? Patient Privacy After Clinical Photography.","authors":"Ikenna Nebo, Rachel Ma, Ananya Eeraveni, Tamia L Ward, Jane M Grant-Kels","doi":"10.1016/j.jaad.2026.10.038","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.10.038","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Can You Be My Dermatologist?" Navigating Patient Expectations Following Mohs Micrographic Surgery. “你能做我的皮肤科医生吗？”在莫氏显微摄影手术后引导患者期望。
IF 12.3 1区 医学
Journal of the American Academy of Dermatology Pub Date : 2026-10-19 DOI: 10.1016/j.jaad.2026.09.135
Rafey A Rehman, Sahil Kapur, Hamza Malick, Steven Daveluy, Nahid Y Vidal
{"title":"\"Can You Be My Dermatologist?\" Navigating Patient Expectations Following Mohs Micrographic Surgery.","authors":"Rafey A Rehman, Sahil Kapur, Hamza Malick, Steven Daveluy, Nahid Y Vidal","doi":"10.1016/j.jaad.2026.09.135","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.09.135","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Talquetamab and Tebentafusp Demonstrate Target-Specific Cutaneous Safety Signal Profiles in FAERS. Talquetamab和Tebentafusp在FAERS中显示特异性靶皮肤安全信号谱。
IF 12.3 1区 医学
Journal of the American Academy of Dermatology Pub Date : 2026-10-19 DOI: 10.1016/j.jaad.2026.10.050
Cansu Altınöz Güney, Huriye Aybüke Koç
{"title":"Talquetamab and Tebentafusp Demonstrate Target-Specific Cutaneous Safety Signal Profiles in FAERS.","authors":"Cansu Altınöz Güney, Huriye Aybüke Koç","doi":"10.1016/j.jaad.2026.10.050","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.10.050","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST. 利非利单抗治疗皮肤红斑狼疮的疗效和安全性：随机2期研究AMETHYST的24周结果
IF 12.3 1区 医学
Journal of the American Academy of Dermatology Pub Date : 2026-10-17 DOI: 10.1016/j.jaad.2026.10.035
Joseph F Merola, Victoria P Werth, Benjamin F Chong, Filippa Nyberg, Eric F Morand, David Fivenson, Francois Chasset, Hua Carroll, Qianyun Li, Michael Schindelar, Effie Pournara, Weihong Yang
{"title":"Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST.","authors":"Joseph F Merola, Victoria P Werth, Benjamin F Chong, Filippa Nyberg, Eric F Morand, David Fivenson, Francois Chasset, Hua Carroll, Qianyun Li, Michael Schindelar, Effie Pournara, Weihong Yang","doi":"10.1016/j.jaad.2026.10.035","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.10.035","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous lupus erythematosus (CLE) is a serious autoimmune disease with no approved targeted treatments.</p><p><strong>Objective: </strong>Evaluate the efficacy and safety of litifilimab in AMETHYST Part A (Phase 2).</p><p><strong>Methods: </strong>AMETHYST is a randomized, double-blind, placebo-controlled, Phase 2/3 study that investigates litifilimab in participants with CLE. Participants were randomized to receive litifilimab 225 mg or placebo every 4 weeks during Weeks 0-24. The primary endpoint was the Cutaneous Lupus Activity Investigator's Global Assessment-Revised (CLA-IGA-R) erythema score of 0-1 at Week 16, with several Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-based endpoints at Week 24 as secondary endpoints. Safety was also assessed.</p><p><strong>Results: </strong>Significantly more participants treated with litifilimab achieved clear/almost clear skin (CLA-IGA-R erythema 0-1) than those treated with placebo at Week 16 (14.7% vs 2.9%, P= .0263). Additionally, more participants treated with litifilimab achieved CLASI-70 response vs placebo at Week 24 (21.7% vs 5.8%, P = .0195). Litifilimab was generally well tolerated; safety data were consistent with prior studies.</p><p><strong>Limitations: </strong>Study was not powered to detect statistically significant differences in secondary endpoints.</p><p><strong>Conclusion: </strong>Litifilimab treatment led to greater improvements in skin disease activity vs placebo and was well tolerated in participants with CLE through Week 24.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.3,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Second-opinion pathology review prior to dermatologic surgery: Clinical treatment impact. 皮肤科手术前的第二意见病理学回顾：临床治疗的影响。
IF 12.3 1区 医学
Journal of the American Academy of Dermatology Pub Date : 2026-10-17 DOI: 10.1016/j.jaad.2026.09.081
Sarah Ghadersohi, Michael J Davis, Megan H Trager, Kishwer Nehal, Nicholas Kurtansky, Klaus J Busam, Elizabeth A Quigley, Karen L Connolly
{"title":"Second-opinion pathology review prior to dermatologic surgery: Clinical treatment impact.","authors":"Sarah Ghadersohi, Michael J Davis, Megan H Trager, Kishwer Nehal, Nicholas Kurtansky, Klaus J Busam, Elizabeth A Quigley, Karen L Connolly","doi":"10.1016/j.jaad.2026.09.081","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.09.081","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.3,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书